What is Global Malignant Mesothelioma Therapeutic Market?
The Global Malignant Mesothelioma Therapeutic Market is a specialized sector within the pharmaceutical industry that focuses on the development and distribution of therapies for the treatment of malignant mesothelioma, a rare and aggressive form of cancer that primarily affects the lining of the lungs, heart, and abdomen. This market is a significant component of the global healthcare industry, as it caters to a critical need for effective treatments for this deadly disease. In 2023, the market was valued at a substantial US$ 329.8 million, demonstrating its importance and potential for growth. The market is projected to reach an impressive US$ 532.5 million by 2030, indicating a Compound Annual Growth Rate (CAGR) of 7.0% during the forecast period from 2024 to 2030.
Pemetrexed, Cisplatin, Others in the Global Malignant Mesothelioma Therapeutic Market:
The Global Malignant Mesothelioma Therapeutic Market is primarily driven by the use of key drugs such as Pemetrexed, Cisplatin, and others. Pemetrexed, in particular, has a significant presence in this market, accounting for approximately 50% of the market in 2019. This drug, along with Cisplatin, is commonly used in chemotherapy for the treatment of malignant mesothelioma. These drugs work by inhibiting the growth of cancer cells, thereby helping to control the progression of the disease. The effectiveness of these drugs in treating malignant mesothelioma has led to their widespread use, contributing to the growth of the market.
Pleural Mesothelioma, Peritoneal Mesothelioma, Others in the Global Malignant Mesothelioma Therapeutic Market:
The Global Malignant Mesothelioma Therapeutic Market caters to the treatment of various forms of mesothelioma, including Pleural Mesothelioma, Peritoneal Mesothelioma, and others. Pleural Mesothelioma, which affects the lining of the lungs, is the most common form of this disease, accounting for about 80% of cases in 2019. The treatments available in this market are primarily used for this form of mesothelioma, contributing to the market's growth. However, the market also provides therapies for other forms of mesothelioma, demonstrating its versatility and comprehensive nature.
Global Malignant Mesothelioma Therapeutic Market Outlook:
In terms of geographical distribution, Europe holds the largest share of the Global Malignant Mesothelioma Therapeutic Market, with a sales market share of over 50% in 2019. This dominance can be attributed to the high incidence of malignant mesothelioma in this region, coupled with the presence of advanced healthcare infrastructure and the availability of effective treatments. However, the market is not limited to Europe and extends to other regions as well, reflecting its global reach and significance.
| Report Metric | Details |
| Report Name | Malignant Mesothelioma Therapeutic Market |
| Accounted market size in 2023 | US$ 329.8 million |
| Forecasted market size in 2030 | US$ 532.5 million |
| CAGR | 7.0% |
| Base Year | 2023 |
| Forecasted years | 2024 - 2030 |
| Segment by Type |
|
| Segment by Application |
|
| By Region |
|
| By Company | Eli Lilly, Teva, Sanofi, Bristol-Myers Squibb, Pfizer, Roche, Merck, Ono Pharmaceutical, Mylan, Fresenius Kabi, Sun Pharmaceuticals |
| Forecast units | USD million in value |
| Report coverage | Revenue and volume forecast, company share, competitive landscape, growth factors and trends |
